for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Ying Han, MD, PhD
Headshot of Ying Han
Ying Han



Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.


The DECLARE Trial is a prospective 1:1 randomized, parallel design, double-masked clinical trial to compare endothelial cell density (ECD), intraocular pressure (IOP) and metagenomic RNA deep sequencing (MDS) between sulcus and anterior chamber (AC) tube placement after glaucoma drainage device (GDD) implantation.

The trial has fixed sample size with 12 months follow-up for primary outcome assessment and trial participants will continue to be followed to the end of grant cycle with a total of 24 months follow-up.

Patients will be randomized to 2 tube locations for GDD implantation:

  • Tube placed in the AC
  • Tube placed in ciliary sulcus
  • Stratification: by clinical center and type of surgery (GDD alone vs GDD combined with phacoemulsification). Stratified randomization by clinical center is to ensure that a similar number of subjects will be randomized to either sulcus tube or AC tube placement for a specific clinical center. Because eyes undergoing a combined phacoemulsification with GDD implantation may be associate with larger ECL from phacoemulsification, stratified by surgery type is to ensure two tube location groups similar number of study eyes that will undergo a combined phacoemulsification with GDD implantation.


Glaucoma, glaucoma drainage device, endothelial cell density, endothelial cell loss, intraocular pressure, Sulcus tube placement, Anterior chamber (AC) tube placement


You can join if…

Open to people ages 18 years and up

  • Medically uncontrolled glaucoma requiring GDD or GDD combined with phacoemulsification as the planned surgical procedure
  • Candidate for GDD implantation for ciliary sulcus and AC tube
  • Age greater than or equal to 18 years old

You CAN'T join if...

  • Preexisting corneal condition that would affect the corneal endothelium or previous corneal transplant
  • Previous GDD implantation or Xen Gel Stent or placement of Cypass Micro-stent or Preserflo MicroShunt
  • Previous trabeculectomy and/or minimally invasive glaucoma surgery within the past 6 months
  • AC intraocular lens
  • Presence of nanophthalmos, uncontrolled uveitis, silicone oil, Sturge-Weber syndrome or other conditions associated with elevated episcleral venous pressure
  • Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
  • No light perception vision in the study eye or fellow eye visual acuity < 20/200
  • Need for glaucoma surgery combined with other ocular procedures (i.e. corneal transplant, or retinal surgery) or anticipated need for additional ocular surgery


  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Prism Eye Institute, University of Toronto not yet accepting patients
    Toronto Canada

Lead Scientist at UCSF

  • Ying Han, MD, PhD
    Dr. Ying Han is an ophthalmologist who specializes in treating glaucoma, including medical, laser and surgical therapies. She has expertise in evaluating and treating cataracts as well. In her research, Han evaluates new drug delivery and new surgical procedures for glaucoma. She's also interested in screening and treatment of glaucoma to prevent vision loss.


accepting new patients
Start Date
Completion Date
University of Pennsylvania
Study Type
Expecting 226 study participants
Last Updated